Momordica charantia for type 2 diabetes mellitus: hypoglycemic efficacy and safety in patients with type 2 diabetes mellitus
Kim SK, Jung J, Jung JH, Yoon N, Kang SS
Published in Complementary Therapies in Medicine
Methodology
Randomized, placebo-controlled trial of bitter melon extract as adjuvant therapy over 12 weeks.
Key Findings
HbA1c was unchanged versus placebo; mean fasting glucose fell in the bitter melon group (p = 0.014). No serious adverse events.
Conclusions
Bitter melon extract lowered fasting glucose but did not change HbA1c over 12 weeks.
Limitations
Single centre, modest sample, no HbA1c benefit despite fasting glucose change.
Supplements Studied
After treatment with bitter melon extract for 12 weeks, the HbA1c levels of the bitter melon and placebo groups remained unchanged; however, the average fasting glucose level of the bitter melon group decreased (p = 0.014).
Outcomes Measured
the average fasting glucose level of the bitter melon group decreased (p = 0.014)
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.